Expanded clinical-grade membrane-bound IL-21/4-1BBL NK cell products exhibit activity against acute myeloid leukemia in vivo.,European Journal of Immunology

当前位置： X-MOL 学术 › Eur. J. Immunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Expanded clinical-grade membrane-bound IL-21/4-1BBL NK cell products exhibit activity against acute myeloid leukemia in vivo.
European Journal of Immunology ( IF 4.5 ) Pub Date : 2020-05-01 , DOI: 10.1002/eji.201948375
Xiang-Yu Zhao _{1,

2} , Qian Jiang ₁ , Hao Jiang ₁ , Li-Juan Hu ₁ , Ting Zhao ₁ , Xing-Xing Yu _{1,

3} , Xiao-Jun Huang _{1,

2,

3}

Affiliation

Adoptive NK cell infusion is a promising immunotherapy for acute myeloid leukemia (AML) patients. The aim of this study was to test the activity of clinical‐grade membrane‐bound IL‐21/4‐1BBL‐expanded NK cell products against AML in vivo.

中文翻译：